SCA
AGN

Salient Capital Advisors’s Allergan plc AGN Stock Holding History

Salient Capital Advisors’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,720
Closed -$411K – 255
2017
Q1 		$411K Buy
+1,720
New +$401K 0.01% 198
2015
Q3 		– Sell
-889
Closed -$270K – 269
2015
Q2 		$270K Buy
+889
New +$265K 0.01% 227

Other funds holding AGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Salient Capital Advisors's AGN Position: Q2 2017 in Review

Salient Capital Advisors sold out of Allergan plc (AGN) in Q2 2017, closing a stake of 1,720 shares — an estimated $411K sold.

Salient Capital Advisors first reported a position in AGN in Q2 2015 and held it in 2 quarters. The position peaked at $411K in Q1 2017. 1,115 funds tracked by Wall St. Rank hold AGN as of Q2 2017.

  • Salient Capital Advisors reported no remaining Allergan plc position as of Q2 2017 after selling out during the quarter.
  • Salient Capital Advisors sold 1,720 Allergan plc shares in Q2 2017, an estimated $411K.
  • Salient Capital Advisors first reported a position in Allergan plc in Q2 2015 and held it in 2 quarters.
  • Salient Capital Advisors's Allergan plc position peaked at $411K in Q1 2017.
  • 1,115 funds tracked by Wall St. Rank held Allergan plc as of Q2 2017.

Based on Salient Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.